Retrospective Analysis of Risk Factors for Cefoperazone/Sulbactam-Induced Thrombocytopenia in Adult Chinese Patients: A Six-Year Real-World Study
Authors:
Open Access
- 1 September 2024
- journal article
- research article
- Published by Taylor & Francis in Infection and Drug Resistance
- Vol. ume 17, 3901-3911
Abstract
Background: Drug-induced thrombocytopenia is a rare adverse reaction of drug therapy and usually underdiagnosed. Cefoperazone/sulbactam is a compound preparation composed of the third generation of cephalosporin and β-lactamase inhibitor, of which thrombocytopenia is an uncommon but serious adverse reaction. However, the existing literature on cefoperazone/sulbactam-induced thrombocytopenia remains limited, and the specific risk factors associated with this adverse effect have not been thoroughly elucidated. Consequently, this study aims to investigate the clinical characteristics and identify the risk factors for thrombocytopenia in adult patients undergoing cefoperazone/sulbactam therapy. Methods: In this retrospective study, we reviewed patients treated with cefoperazone/sulbactam at Beijing Hospital between January 2017 and June 2023. Patients were categorized into two groups based on the presence or absence of thrombocytopenia: the thrombocytopenia group and the non-thrombocytopenia group. We collected data on demographic features, clinical characteristics, laboratory parameters, treatments, and outcomes. Subsequently, univariate and multivariate logistic regression analyses were performed to identify potential risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Results: In total, 6489 patients were included in this study, and 2.4% (155/6489) developed thrombocytopenia. The results of multivariate analysis showed that cefoperazone/sulbactam therapy duration (d) > 14, PLT (109/L) < 200, daily dose of cefoperazone/sulbactam (g) ≥ 6, TBil (μmoL/L) > 21, AST (U/L) > 35, and use of non-invasive ventilator were risk factors for cefoperazone/sulbactam-induced thrombocytopenia. Conclusion: Despite the low incidence (2.4%), cefoperazone/sulbactam could cause serious thrombocytopenia sometimes accompanied with hemorrhage. In clinical therapy, clinicians should be vigilant in monitoring platelet count, especially for patients with risk factors of cefoperazone/sulbactam-induced thrombocytopenia.Keywords
This publication has 23 references indexed in Scilit:
- Risk factors for thrombocytopenia in patients receiving linezolid therapy: a systematic review and meta-analysisEuropean Journal of Clinical Pharmacology, 2023
- Use of Japanese big data from electronic medical records to investigate risk factors and identify their high-risk combinations for linezolid-induced thrombocytopeniaEuropean Journal of Clinical Pharmacology, 2023
- Risk factors for linezolid-induced thrombocytopenia in adult inpatientsInternational Journal of Clinical Pharmacy, 2021
- A retrospective cohort study to screen linezolid-induced thrombocytopenia in adult patients hospitalized in the Midwestern Region of BrazilHematology, Transfusion and Cell Therapy, 2020
- Cefoperazone-sulbactam and risk of coagulation disorders or bleeding: a retrospective cohort studyExpert Opinion on Drug Safety, 2020
- Cefepime challenge after piperacillin/tazobactam-induced thrombocytopeniaJournal of Thrombosis and Thrombolysis, 2019
- Piperacillin-induced Thrombocytopenia in a Dual Heart and Kidney Transplant Patient: A Case ReportTransplantation Proceedings, 2017
- A retrospective study of the risk factors for linezolid-induced thrombocytopenia and anemiaJournal of Infection and Chemotherapy, 2016
- Antimicrobial Drug-Induced Thrombocytopenia: A Review of the LiteratureSeminars in Thrombosis and Hemostasis, 2012
- Drug-Induced ThrombocytopeniaHematology/Oncology Clinics of North America, 2007